stockrow
Friday 6 November 2026
Export CDIO’s income statement to Excel — free account
Cardio Diagnostics Holdings, Inc.
CDIO Healthcare Biotechnology
Cardio Diagnostics Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14,800.00, down 57.6% from fiscal 2024.
- Revenue
- +23.8%
- EPS
- +47.4%
- Free cash flow
- +2.59%
Quarter to September 2026, against a year earlier
1.65
0.03
−1.79%
Follow CDIO
Alert me
| Dec '17 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 4 | 5 | 3 |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | 0.00 | 0.00 | 0.00 | 1,036.37 | 318.47 |
Altman Z-Score |
— | — | (1.98) | 3.25 | 9.31 | (3.61) |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | 29.94 | (1.56) | (16.51) | 2.25 | (4.17) |
P/Operating CF |
— | (7,958.34) | (1.09) | (34.58) | (25.98) | (3.48) |
Beneish M-Score |
— | — | — | — | (2.27) | (3.53) |
P/B ratio |
— | 3,506.47 | 0.79 | 19.71 | 3.78 | 0.68 |
Price to Tangible BV |
— | 3,506.47 | 0.80 | 19.85 | 3.79 | 0.68 |
EV/Sales |
— | 0.00 | 0.00 | 0.00 | 812.09 | (24.52) |
EV/EBITDA |
— | 0.00 | 0.16 | 0.00 | 0.00 | 0.06 |
EV/Operating CF |
— | 0.00 | 0.14 | (10.05) | (5.68) | 0.06 |
EV/FCF |
— | 0.00 | 0.14 | (9.12) | (5.44) | 0.06 |
Quick Ratio |
— | 15.15 | 2.11 | 1.53 | 12.42 | 8.46 |
Current Ratio |
— | 23.70 | 3.02 | 3.29 | 13.92 | 9.79 |
Net Debt/EBITDA |
— | 0.85 | 0.91 | 0.18 | 0.97 | 0.84 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.94 | 1.09 | 0.68 | 0.60 | 0.88 |
Capex/Depreciation |
— | 0.00 | 0.00 | (5.16) | (0.78) | (0.47) |
Interest Coverage |
— | (1,240.80) | — | (1.08) | (449.78) | (438.11) |
| — | 0.00% | (173.60%) | (230.77%) | (133.97%) | (78.62%) | |
| — | (112.60%) | (126.80%) | (156.40%) | (111.20%) | (70.70%) | |
ROIC |
— | (69.83%) | (1,543.33%) | (270.31%) | (302.18%) | (217.55%) |
Return on Tangible Assets |
— | (80.61%) | (118.36%) | (335.54%) | (94.92%) | (108.02%) |
Average Days of Receivables |
— | 365.00 | 0.00 | 106.73 | 194.53 | 199.76 |
Research and Development Expense of Revenue |
— | 3,500.00% | 4,040.00% | 849.12% | 653.30% | 4,332.43% |
Selling, General and Administrative Expense of Revenue |
— | 63,766.67% | 449,300.00% | 41,492.40% | 23,361.32% | 39,138.51% |
Intangible Assets out of Total Assets |
0.00 | 0.05 | 0.01 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 6,666.67% | 0.00% | 7,481.29% | 7,424.64% | 744.59% |
Graham Net Nets |
— | (0.03) | 1.16 | 0.02 | 0.21 | 1.08 |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | (3.97%) | (137.37%) | (23.97%) | (39.13%) | (137.27%) |
Free Cash Flow Yield |
— | 0.00% | (150.07%) | (10.72%) | (14.40%) | (124.63%) |
Revenue per Share |
— | 0.02 | 0.01 | 0.04 | 0.04 | 0.01 |
Operating CF per Share |
— | (15.12) | (49.52) | (13.43) | (5.57) | (3.27) |
Capex per Share |
— | 0.00 | 0.00 | (1.36) | (0.24) | (0.11) |
Free Cash Flow per Share |
— | (15.12) | (49.52) | (14.79) | (5.81) | (3.38) |
Cash per Share |
— | 13.25 | 40.05 | 3.04 | 8.74 | 2.92 |
Shareholders Equity per Share |
— | 27.60 | 41.85 | 7.00 | 10.67 | 3.98 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 27.60 | 41.85 | 7.00 | 10.67 | 3.98 |
Free Cash Flow |
— | (0.59) | (5.09) | (6.25) | (5.21) | (5.91) |
Working Capital |
— | 0.77 | 3.94 | 1.92 | 8.16 | 5.32 |
Capital Expenditures |
— | (0.11) | (0.08) | (0.58) | (0.21) | (0.19) |
Net Current Asset Value |
— | 0.77 | 3.94 | 1.26 | 7.73 | 5.13 |
EV/EBIT |
— | 0.00 | 0.16 | 0.00 | 0.00 | 0.06 |
Capex to Sales |
— | 0.00 | 0.00 | 33.67 | 6.15 | 12.66 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||
Depreciation/Fixed assets |
— | 0.00 | 0.00 | 0.20 | 0.41 | 0.57 |
Cash ROIC |
— | (37.02%) | (60.47%) | (147.30%) | (29.96%) | (48.94%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 5.80 | 2.96 | 1.11 |
Accounts Payable Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | 0.00 | — | — | — |
Average Receivables |
— | — | — | 0.00 | 0.01 | 0.01 |
Average Payables |
— | — | 0.57 | 0.67 | 0.17 | 0.09 |
Average Assets |
— | 0.55 | 3.68 | 5.36 | 7.54 | 9.19 |
Average Common Equity |
— | — | 2.68 | 3.63 | 6.26 | 8.27 |
Columns are period end dates · fundamentals updated 6 Nov 2026